BLACKSMITH MEDICINES, INC. - FG-2101: A FIRST-IN-CLASS LPXC INHIBITOR FOR THE TREATMENT OF MDR GRAMNEGATIVE URINARY TRACT INFECTIONS.

On Dec 18, 2025, Department of Health and Human Services obligated $10,977,909 to BLACKSMITH MEDICINES, INC. for fg-2101: a first-in-class lpxc inhibitor for the treatment of mdr gramnegative urinary tract infections.. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition with 30 offers received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SAN DIEGO, CA. The contract is scheduled through Dec 31, 2026 — approximately 8 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541715 — related awards are listed below.